Search

Your search keyword '"Bozkurt, İ"' showing total 8 results
Start Over Author "Bozkurt, İ" Topic male
8 results on '"Bozkurt, İ"'

1. Factors associated with ventilator-associated events: an international multicenter prospective cohort study

Author

Rello, J., Ramirez-Estrada, S., Romero, A., Arvaniti, K., Koulenti, D., Nseir, S., Oztoprak, N., Bouadma, L., Vidaur, L., Lagunes, L., Pena-Lopez, Y., Almirante, B., Bastug, A., Bassetti, M., Bozkurt, I., Dimopoulos, G., Inan, A., Oikonomou, M., Poulakou, G., Thompson, D., Torrivilla, E., Totorika, I., and Varghese, V.

Subjects
Male, Microbiology (medical), Prevention bundles, medicine.medical_specialty, Critical Care, Turkey, Midazolam, medicine.medical_treatment, Mechanical ventilation, Safety, Selective digestive decontamination, Ventilator-associated pneumonia, Aged, Female, France, Greece, Home Care Services, Humans, Intensive Care Units, Length of Stay, Middle Aged, Pneumonia, Ventilator-Associated, Proportional Hazards Models, Prospective Studies, Respiration, Artificial, Spain, Interquartile range, Internal medicine, Intensive care, medicine, Prospective cohort study, Proportional hazards model, business.industry, Respiration, Hazard ratio, Pneumonia, General Medicine, medicine.disease, Ventilator-Associated, Infectious Diseases, Artificial, Cohort, business
Abstract

A secondary analysis of a prospective multicenter cohort was performed in six intensive care units (ICU) in four European countries (France, Greece, Spain and Turkey). The main objective was to identify factors associated with ventilator-associated events (VAEs) in adults who underwent mechanical ventilation (MV) ≥ 48 h. Secondary objectives were to identify: variables influencing VAE in the subpopulation with endotracheal intubation and in those subjects who were ventilated > 7 days. Subjects who had undergone MV ≥ 48 h were included. In subjects with multiple episodes of MV, only the first one was eligible. The adult definitions for VAEs were adjusted to the 2015 update of the CDC’s 2013 National Healthcare Safety Network Association. Factors associated with VAE were estimated through multivariate Cox proportional hazards analysis. Among 163 adults (42 tracheostomies), 76 VAEs (34.9 VAEs/1,000 ventilator-days) were documented: 9 were Ventilator-Associated Conditions (VAC) and 67 Infection-related Ventilator-Associated Complications (IVAC)-plus (9 only IVAC and 58 Possible Ventilator-Associated Pneumonia). VAEs developed after a median of 6 days (interquartile range: 4–9). VAEs were independently associated with long-acting sedative/analgesic drugs (Hazard Ratio [HR]: 4.30), selective digestive decontamination (SDD) (HR: 0.38), and surgical/trauma admission (HR: 2.30). Among 116 subjects with endotracheal tube, SDD (HR: 0.21) and surgical/trauma admission (HR: 3.11) remained associated with VAE. Among 102 subjects ventilated >7 days, only long-acting sedative/analgesic agents (HR: 8.69) remained independently associated with VAE. In summary, SDD implementation and long-acting analgesic/sedative agents restriction prescription may prevent early and late VAEs, respectively. Bundles developed to prevent VAEs should include these two interventions.

Published
2019
Full Text
View/download PDF

2. Assessing predictive accuracy for outcomes of ventilator-associated events in an international cohort: the EUVAE study

Author

Ramirez-Estrada, S., Lagunes, L., Pena-Lopez, Y., Vahedian-Azimi, A., Nseir, S., Arvaniti, K., Bastug, A., Totorika, I., Oztoprak, N., Bouadma, L., Koulenti, D., Rello, J., Asumaninan, Gragera, B. A., Poulakou, G., Dimopoulos, G., Bozkurt, I., Muzlovic, I., Vidaur, L., Oikonomou, M., and Bassetti, M.

Subjects
Ventilator-associated events, Male, medicine.medical_specialty, Original, Atelectasis, Critical Care and Intensive Care Medicine, Hypoxemia, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Predictive Value of Tests, Anesthesiology, Intensive care, Medicine, Ventilator-associated pneumonia, Humans, 030212 general & internal medicine, Prospective Studies, Bronchitis, Diagnostic Techniques and Procedures, Aged, Surveillance, Ventilator-associated tracheobronchitis, Anti-Bacterial Agents, Female, Middle Aged, Pneumonia, Ventilator-Associated, Respiration, Artificial, business.industry, Respiration, Pneumonia, medicine.disease, Ventilator-Associated, 030228 respiratory system, Emergency medicine, Cohort, Artificial, medicine.symptom, business, Complication
Abstract

Purpose To analyze the impact on patient outcome of ventilator-associated events (VAEs) as defined by the Centers for Disease Control and Prevention (CDC) in 2008, 2013, and the correlation with ventilator-associated pneumonia (VAP) or tracheobronchitis (VAT). Methods This was a prospective, observational, multicenter, international study conducted at 13 intensive care units (ICUs); thirty consecutive adults mechanically ventilated for ≥ 48 h per site were eligible, with daily follow-up being recorded in a collaborative web database; VAEs were assessed using the 2013 CDC classification and its 2015 update. Results A total of 2856 ventilator days in 244 patients were analyzed, identifying 33 VAP and 51 VAT episodes; 30-day ICU mortality was significantly higher (42.8 vs. 19.6%, p

Published
2018

3. Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey

Author

Karacaer ZAUID- ORCID: 0000-0002-2658-4679, Cakir B, Erdem H, Ugurlu K, Durmus G, Ince NK, Ozturk C, Hasbun R, Batirel A, Yilmaz EM, Bozkurt I, Sunbul M, Aynioglu A, Atilla A, Erbay A, Inci A, Kader C, Tigen ET, Karaahmetoglu G, Coskuner SA, Dik E, Tarakci H, Tosun S, Korkmaz F, Kolgelier S, Karadag FY, Erol S, Turker K, Necan C, Sahin AM, Ergen P, Iskender G, Korkmaz P, Eroglu EG, Durdu Y, Ulug M, Deniz SS, Koc F, Alpat SN, Oztoprak N, Evirgen O, Sozen H, Dogan M, Kaya S, and Altindis M

Subjects
Adult, Aged, Antiviral Agents/therapeutic use, Cross-Sectional Studies, Female, Health Status Indicators, Hepatitis B, Chronic/drug therapy/psychology, Humans, Interviews as Topic, Male, Middle Aged, Prospective Studies, Quality of Life, Turkey
Abstract

BACKGROUND: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors. METHODS: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant. RESULTS: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided. CONCLUSIONS: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.

Published
2016

4. Quality of life and related factors among chronic hepatitis B-infected patients: A multi-center study, Turkey

Author

Karacaer, Z., Cakir, B., Erdem, H., Ugurlu, K., Durmus, G., Ince, N.K., Ozturk, C., Hasbun, R., Batirel, A., Yilmaz, E.M., Bozkurt, I., Sunbul, M., Aynioglu, A., Atilla, A., Erbay, A., Inci, A., Kader, C., Tigen, E.T., Karaahmetoglu, G., Coskuner, S.A., Dik, E., Tarakci, H., Tosun, S., Korkmaz, F., Kolgelier, S., Karadag, F.Y., Erol, S., Turker, K., Necan, Ceyda, Sahin, A.M., Ergen, P., Iskender, G., Korkmaz, P., Eroglu, E.G., Durdu, Y., Ulug, M., Deniz, S.S., Koc, F., Alpat, S.N., Oztoprak, N., Evirgen, O., Sozen, H., Dogan, M., Kaya, S., Altindis, M., Aslan, E., Tekin, R., Sezer, B.E., Ozdemir, K., Ersoz, G., Sahin, A., Celik, I., Aydin, E., Bastug, A., Harman, R., Ozkaya, H.D., Parlak, E., Yavuz, I., Sacar, S., Comoglu, S., Yenilmez, E., Sirmatel, F., Balkan, I.I., Alpay, Y., Hatipoglu, M., Denk, A., Senol, G., Bitirgen, M., Geyik, M.F., Guner, R., Kadanali, A., Karakas, A., Namiduru, M., Udurgucu, H., Boluktas, R.P., Karagoz, E., and Ormeci, N.

Subjects
Quality of life, antivirus agent, Adult, Male, demography, Turkey, quality of life assessment, psychology, Antiviral Agents, Article, Turkey (republic), Interviews as Topic, Hepatitis B, Chronic, antiviral therapy, middle aged, cross-sectional study, Health Status Indicators, Humans, chronic hepatitis B, controlled study, human, Prospective Studies, The Hepatitis B Quality of Life Instrument, Aged, Hepatitis B Quality of Life, interview, clinical trial, major clinical study, Chronic hepatitis B infection, hepatitis B surface antigen, female, multicenter study, Cross-Sectional Studies, Short Form 36, prospective study, health status indicator
Abstract

Background: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors. Methods: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant. Results: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided. Conclusions: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients. © 2016 The Author(s).

Published
2016

5. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data

Author

Muthuri, SG, Venkatesan, S, Myles, PR, Leonardi-Bee, J, Al Khuwaitir, TSA, Al Mamun, A, Anovadiya, AP, Azziz-Baumgartner, E, Báez, C, Bassetti, M, Beovic, B, Bertisch, B, Bonmarin, I, Booy, R, Borja-Aburto, VH, Burgmann, H, Cao, B, Carratala, J, Denholm, JT, Dominguez, SR, Duarte, PAD, Dubnov-Raz, G, Echavarria, M, Fanella, S, Gao, Z, Gérardin, P, Giannella, M, Gubbels, S, Herberg, J, Higuera Iglesias, AL, Hoger, PH, Hu, X, Islam, QT, Jiménez, MF, Kandeel, A, Keijzers, G, Khalili, H, Knight, M, Kudo, K, Kusznierz, G, Kuzman, I, Kwan, AMC, Amine, IL, Langenegger, E, Lankarani, KB, Leo, Y-S, Linko, R, Liu, P, Madanat, F, Mayo-Montero, E, McGeer, A, Memish, Z, Metan, G, Mickiene, A, Mikic, D, Mohn, KGI, Moradi, A, Nymadawa, P, Oliva, ME, Ozkan, M, Parekh, D, Paul, M, Polack, FP, Rath, BA, Rodríguez, AH, Sarrouf, EB, Seale, AC, Sertogullarindan, B, Siqueira, MM, Skret-Magierlo, J, Stephan, F, Talarek, E, Tang, JW, To, KKW, Torres, A, Törün, SH, Tran, D, Uyeki, TM, van Zwol, A, Vaudry, W, Vidmar, T, Yokota, RTC, Zarogoulidis, P, Nguyen-van-Tam, JS, Aguiar-Oliveira, ML, Al Masri, M, Amin, R, Araújo, WN, Ballester-Orcal, E, Bantar, C, Bao, J, Barhoush, MM, Basher, A, Bautista, E, Bettinger, J, Bingisser, R, Bouza, E, Bozkurt, I, Celjuska-Tošev, E, Chan, KKC, Chen, Y, Chinbayar, T, Cilloniz, C, Cox, RJ, Cuezzo, MR, Cui, W, Dashti-Khavidaki, S, du, B, El Rhaffouli, H, Escobar, H, Florek-Michalska, A, Fraser, J, Gerrard, J, Gormley, S, Götberg, S, Hoffmann, M, Honarvar, B, Hu, J, Kemen, C, Khandaker, G, Koay, KSC, Kojic, M, Kyaw, WM, Leibovici, L, Li, H, Li, X-L, Libster, R, Loh, TP, Macbeth, D, Maltezos, E, Manabe, T, Marcone, DN, Marczynska, M, Mastalir, FP, Moghadami, M, Moriconi, L, Ozbay, B, Pečavar, B, Poeppl, W, Poliquin, PG, Rahman, M, Rascon-Pacheco, A, Refaey, S, Schweiger, B, Smith, FG, Somer, A, Souza, TML, Tabarsi, P, Tripathi, CB, Velyvyte, D, Viasus, D, Yu, Q, Yuen, K-Y, Zhang, W, Zuo, W, Pediatric surgery, CCA - Innovative therapy, Muthuri, Stella G., Venkatesan, Sudhir, Myles, Puja R., Leonardi-Bee, Jo, Al Khuwaitir, Tarig S. A., Al Mamun, Adbullah, Anovadiya, Ashish P., Azziz-Baumgartner, Eduardo, Báez, Clarisa, Bassetti, Matteo, Beovic, Bojana, Bertisch, Barbara, Bonmarin, Isabelle, Booy, Robert, Borja-Aburto, Victor H., Burgmann, Heinz, Cao, Bin, Carratala, Jordi, Denholm, Justin T., Dominguez, Samuel R., Duarte, Pericles A.D., Dubnov-Raz, Gal, Echavarria, Marcela, Fanella, Sergio, Gao, Zhancheng, Gérardin, Patrick, Giannella, Maddalena, Gubbels, Sophie, Herberg, Jethro, Higuera Iglesias, Anjarath L., Hoger, Peter H., Hu, Xiaoyun, Islam, Quazi T., Jiménez, Mirela F., Kandeel, Amr, Keijzers, Gerben, Khalili, Hossein, Knight, Marian, Kudo, Koichiro, Kusznierz, Gabriela, Kuzman, Ilija, Kwan, Arthur M. C., Amine, Idriss Lahlou, Langenegger, Eduard, Lankarani, Kamran B., Leo, Yee-Sin, Linko, Rita, Liu, Pei, Madanat, Fari, Mayo-Montero, Elga, Mcgeer, Allison, Memish, Ziad, Metan, Gokhan, Mickiene, Aukse, Mikic, Dragan, Mohn, Kristin G.I., Moradi, Ahmadreza, Nymadawa, Pagbajabyn, Oliva, Maria E., Ozkan, Mehpare, Parekh, Dhruv, Paul, Mical, Polack, Fernando P., Rath, Barbara A., Rodríguez, Alejandro H., Sarrouf, Elena B., Seale, Anna C., Sertogullarindan, Bunyamin, Siqueira, Marilda M., Skret-Magierlo, Joanna, Stephan, Frank, Talarek, Ewa, Tang, Julian W., To, Kelvin K.W., Torres, Antoni, Törün, Selda H., Tran, Dat, Uyeki, Timothy M., van Zwol, Annelie, Vaudry, Wendy, Vidmar, Tjasa, Yokota, Renata T.C., Zarogoulidis, Paul, Nguyen-van-Tam, Jonathan S, Aguiar-Oliveira, Maria de Lourde, Al Masri, Malakita, Amin, Robed, Araújo, Wildo N., Ballester-Orcal, Elena, Bantar, Carlo, Bao, Jing, Barhoush, Mazen M., Basher, Ariful, Bautista, Edgar, Bettinger, Julie, Bingisser, Roland, Bouza, Emilio, Bozkurt, Ilkay, Celjuska-Tošev, Elvira, Chan, Kenny K.C., Chen, Yusheng, Chinbayar, Tserendorj, Cilloniz, Catia, Cox, Rebecca J., Cuezzo, María R., Cui, Wei, Dashti-Khavidaki, Simin, Du, Bin, El Rhaffouli, Hicham, Escobar, Hernan, Florek-Michalska, Agnieszka, Fraser, Jame, Gerrard, John, Gormley, Stuart, Götberg, Sandra, Hoffmann, Matthia, Honarvar, Behnam, Hu, Jianmin, Kemen, Christoph, Khandaker, Gulam, Koay, Evelyn S. C., Kojic, Miroslav, Kyaw, Win M., Leibovici, Leonard, Li, Hongru, Li, Xiao-Li, Libster, Romina, Loh, Tze P., Macbeth, Deborough, Maltezos, Efstratio, Manabe, Toshie, Marcone, Débora N., Marczynska, Magdalena, Mastalir, Fabiane P., Moghadami, Mohsen, Moriconi, Lilian, Ozbay, Bulent, Pečavar, Blaž, Poeppl, Wolfgang, Poliquin, Philippe G., Rahman, Mahmudur, Rascon-Pacheco, Alberto, Refaey, Samir, Schweiger, Brunhilde, Smith, Fang G., Somer, Ayper, Souza, Thiago M. L., Tabarsi, Payam, Tripathi, Chandrabhanu B., Velyvyte, Daiva, Viasus, Diego, Yu, Qin, Yuen, Kwok-Yung, Zhang, Wei, and Zuo, Wei

Subjects
Male, ANTIVIRAL TREATMENT, IMPACT, Respiratory System, CHILDREN, Neuraminidase inhibitors, Pandemic influenza, Mortality, Meta-analysis, medicine.disease_cause, THERAPY, chemistry.chemical_compound, Influenza A Virus, H1N1 Subtype, 0302 clinical medicine, Pandemic, Influenza A Virus, Influenza A virus, Zanamivir, 030212 general & internal medicine, Enzyme Inhibitors, Child, OUTCOMES, 0303 health sciences, biology, Neuraminidase inhibitor, Medicine (all), virus diseases, Middle Aged, 3. Good health, Hospitalization, Treatment Outcome, Female, Life Sciences & Biomedicine, Adolescent, Adult, Antiviral Agents, Humans, Influenza, Human, Neuraminidase, Oseltamivir, Proportional Hazards Models, Young Adult, Pandemics, Pulmonary and Respiratory Medicine, Human, medicine.drug, medicine.medical_specialty, medicine.drug_class, PANDEMIC INFLUENZA, Article, PRIDE Consortium Investigators, 03 medical and health sciences, Critical Care Medicine, General & Internal Medicine, Internal medicine, medicine, H1N1 Subtype, Intensive care medicine, Science & Technology, 030306 microbiology, business.industry, STEM-CELL TRANSPLANTATION, ADULTS, Odds ratio, Influenza, chemistry, RISK-FACTORS, biology.protein, business
Abstract

Background: Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, but evidence for their effectiveness in reducing mortality is uncertain. We did a meta-analysis of individual participant data to investigate the association between use of neuraminidase inhibitors and mortality in patients admitted to hospital with pandemic influenza A H1N1pdm09 virus infection. Methods: We assembled data for patients (all ages) admitted to hospital worldwide with laboratory confirmed or clinically diagnosed pandemic influenza A H1N1pdm09 virus infection. We identified potential data contributors from an earlier systematic review of reported studies addressing the same research question. In our systematic review, eligible studies were done between March 1, 2009 (Mexico), or April 1, 2009 (rest of the world), until the WHO declaration of the end of the pandemic (Aug 10, 2010); however, we continued to receive data up to March 14, 2011, from ongoing studies. We did a meta-analysis of individual participant data to assess the association between neuraminidase inhibitor treatment and mortality (primary outcome), adjusting for both treatment propensity and potential confounders, using generalised linear mixed modelling. We assessed the association with time to treatment using time-dependent Cox regression shared frailty modelling. Findings: We included data for 29234 patients from 78 studies of patients admitted to hospital between Jan 2, 2009, and March 14, 2011. Compared with no treatment, neuraminidase inhibitor treatment (irrespective of timing) was associated with a reduction in mortality risk (adjusted odds ratio [OR] 0·81; 95% CI 0·70-0·93; p=0·0024). Compared with later treatment, early treatment (within 2 days of symptom onset) was associated with a reduction in mortality risk (adjusted OR 0·48; 95% CI 0·41-0·56; p

Published
2014
Full Text
View/download PDF

6. Can prenatal exposure to a 900 MHz electromagnetic field affect the morphology of the spleen and thymus, and alter biomarkers of oxidative damage in 21-day-old male rats?

Author

Hancı, H, Türedi, S, Topal, Z, Mercantepe, T, Bozkurt, İ, Kaya, H, Ersöz, Ş, Ünal, B, and Odacı, E

Subjects
ELECTROMAGNETIC fields, SPLEEN, THYMUS, BIOMARKERS, OXIDATIVE stress, ELECTRON microscopy
Abstract

We investigated the effects of a 900 Megahertz (MHz) electromagnetic field (EMF), applied during the prenatal period, on the spleen and thymus of 21-day-old male rat pups. Pregnant Sprague-Dawley rats were divided into control and EMF groups. We applied 900 MHz EMF for 1 h/day to the EMF group of pregnant rats. Newborn male rat pups were removed from their mothers and sacrificed on postnatal day 21. Spleen and thymus tissues were excised and examined. Compared to the control group, thymus tissue malondialdehyde levels were significantly higher in the group exposed to EMF, while glutathione levels were significantly decreased. Increased malondialdehyde and glutathione levels were observed in splenic tissue of rats exposed to EMF, while a significant decrease occurred in superoxide dismutase values compared to controls. Transmission electron microscopy showed pathological changes in cell morphology in the thymic and splenic tissues of newborn rats exposed to EMF. Exposure to 900 MHz EMF during the prenatal period can cause pathological and biochemical changes that may compromise the development of the male rat thymus and spleen. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

7. Portraying infective endocarditis

Author

Ilker Inanc Balkan, Najada Como, André Silva-Pinto, Antonio Cascio, Canan Agalar, Meliha Meric-Koc, Tatjana Lejko Zupanc, Oday Abu Ajamieh, Simin Aysel Florescu, Selma Tosun, Meltem Taşbakan, Asuman Inan, Rosa Fontana Del Vecchio, Edmond Puca, Güven Çelebi, Ayse Sagmak-Tartar, Abdullah Umut Pekok, Yasemin Cag, Gülden Ersöz, Sumeyra Karakus, Safak Ozer-Balin, Jamal Wadi, Sukran Kose, Yves Hansmann, Hacer Deniz Ozkaya, Nefise Oztoprak, Hakan Erdem, Serkan Oncu, Jesper Damsgaard Gunst, Yvon Ruch, Aysegul Erdem, Gilda Tonziello, Ayse Batirel, Rahmet Guner, Irina Magdalena Dumitru, Lurdes Santos, Raquel Duro, Nesrin Ghanem-Zoubi, Arjeta Dedej, Serda Gulsun, Mustafa Dogan, Necla Tulek, Alper Şener, Pedro Palma Martins, Ilkay Bozkurt, Deborah Konopnicki, Fatma Sirmatel, Xavier Argemi, Meltem Avci, Fahad Almajid, Recep Tekin, Nicola Petrosillo, Corneliu Petru Popescu, Ayse Kaya-Kalem, Imran Hasanoglu, Atilla Iyisoy, Jean Philippe Mazzucotelli, Ejaz Ahmed Khan, Sema Sarı, Derya Ozturk-Engin, Nicolas Dauby, Erdem H., Puca E., Ruch Y., Santos L., Ghanem-Zoubi N., Argemi X., Hansmann Y., Guner R., Tonziello G., Mazzucotelli J.-P., Como N., Kose S., Batirel A., Inan A., Tulek N., Pekok A.U., Khan E.A., Iyisoy A., Meric-Koc M., Kaya-Kalem A., Martins P.P., Hasanoglu I., Silva-Pinto A., Oztoprak N., Duro R., Almajid F., Dogan M., Dauby N., Gunst J.D., Tekin R., Konopnicki D., Petrosillo N., Bozkurt I., Wadi J., Popescu C., Balkan I.I., Ozer-Balin S., Zupanc T.L., Cascio A., Dumitru I.M., Erdem A., Ersoz G., Tasbakan M., Ajamieh O.A., Sirmatel F., Florescu S., Gulsun S., Ozkaya H.D., Sari S., Tosun S., Avci M., Cag Y., Celebi G., Sagmak-Tartar A., Karakus S., Sener A., Dedej A., Oncu S., Del Vecchio R.F., Ozturk-Engin D., Agalar C., Virulence Bactérienne Précoce : fonctions cellulaires et contrôle de l'infection aigüe et subaigüe, Université de Strasbourg (UNISTRA), Virulence bactérienne précoce : fonctions cellulaires et contrôle de l'infection aiguë et subaiguë, Nanomédecine Régénérative (NanoRegMed), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), MERİÇ KOÇ, MELİHA, İÜC, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Uşak Üniversitesi, Zonguldak Bülent Ecevit Üniversitesi, BAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Sırmatel, Fatma, and OMÜ

Subjects
Male, Internationality, Aucun, Infective endocarditi, medicine.disease_cause, Medical microbiology, 80 and over, Blood culture, Hospital Mortality, Aged, 80 and over, medicine.diagnostic_test, biology, Endocarditis, Bacterial, General Medicine, Sciences bio-médicales et agricoles, Middle Aged, Staphylococcal Infections, Sciences du Vivant [q-bio]/Microbiologie et Parasitologie, Viridans Streptococci, Catheter, Infectious Diseases, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Staphylococcus aureus, Infective endocarditis, Aortic Valve, Mitral Valve, Female, Microbiology (medical), Adult, medicine.medical_specialty, Prosthesis-Related Infections, Adolescent, aureus, Young Adult, Internal medicine, medicine, Humans, results of multinational ID-IRI study-, EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, cilt.38, ss.1753-1763, 2019 [Erdem H., Puca E., Ruch Y., Santos L., Ghanem-Zoubi N., Argemi X., Hansmann Y., Guner R., Tonziello G., Mazzucotelli J., et al., -Portraying infective endocarditis], Prosthetic, Aged, Native Valve Endocarditis, Bacteria, business.industry, Endocarditis, Bacterial, medicine.disease, biology.organism_classification, S. aureus, Viridans streptococci, business, Native
Abstract

Infective endocarditis is a growing problem with many shifts due to ever-increasing comorbid illnesses, invasive procedures, and increase in the elderly. We performed this multinational study to depict definite infective endocarditis. Adult patients with definite endocarditis hospitalized between January 1, 2015, and October 1, 2018, were included from 41 hospitals in 13 countries. We included microbiological features, types and severity of the disease, complications, but excluded therapeutic parameters. A total of 867 patients were included. A total of 631 (72.8%) patients had native valve endocarditis (NVE), 214 (24.7%) patients had prosthetic valve endocarditis (PVE), 21 (2.4%) patients had pacemaker lead endocarditis, and 1 patient had catheter port endocarditis. Eighteen percent of NVE patients were hospital-acquired. PVE patients were classified as early-onset in 24.9%. A total of 385 (44.4%) patients had major embolic events, most frequently to the brain (n = 227, 26.3%). Blood cultures yielded pathogens in 766 (88.4%). In 101 (11.6%) patients, blood cultures were negative. Molecular testing of vegetations disclosed pathogens in 65 cases. Overall, 795 (91.7%) endocarditis patients had any identified pathogen. Leading pathogens (Staphylococcus aureus (n = 267, 33.6%), Streptococcus viridans (n = 149, 18.7%), enterococci (n = 128, 16.1%), coagulase-negative staphylococci (n = 92, 11.6%)) displayed substantial resistance profiles. A total of 132 (15.2%) patients had cardiac abscesses; 693 (79.9%) patients had left-sided endocarditis. Aortic (n = 394, 45.4%) and mitral valves (n = 369, 42.5%) were most frequently involved. Mortality was more common in PVE than NVE (NVE (n = 101, 16%), PVE (n = 49, 22.9%), p = 0.042)., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2019
Full Text
View/download PDF

8. Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey

Author

Ayse Inci, Fatma Yılmaz Karadağ, Pınar Ergen, Saygin Nayman Alpat, Rezan Harman, Ilhami Celik, Filiz Koc, Hakan Erdem, Mehmet Bitirgen, Ilknur Yavuz, Nefise Oztoprak, Ayse Batirel, Banu Cakir, Mustafa Namiduru, Esmeray Mutlu Yilmaz, Kevser Ozdemir, Emsal Aydin, Yasemin Durdu, Kenan Ugurlu, Nevin Ince, Aynur Atilla, Büşra Ergüt Sezer, Emel Aslan, Serpil Erol, Mustafa Hatipoglu, Hatice Udurgucu, Mustafa Sunbul, Ayşe Erbay, Ercan Yenilmez, Hacer Deniz Ozkaya, Yeşim Alpay, Esma Gulesen Eroglu, Mehmet Faruk Geyik, Emine Parlak, Hüseyin Tarakçı, Rodrigo Hasbun, Gunes Senol, Aynur Aynioglu, Ilkay Bozkurt, Necati Örmeci, Recep Tekin, Seher Ayten Coskuner, Gokhan Karaahmetoglu, Ebru Dik, Zehra Karacaer, Suna Seçil Öztürk Deniz, Gulsen Iskender, Selma Tosun, Fatime Korkmaz, Ilker Inanc Balkan, Ergenekon Karagoz, Fatma Sirmatel, Suzan Sacar, Ömer Evirgen, Mustafa Dogan, Ayten Kadanali, Senol Comoglu, Rahmet Guner, Ahmet Şahin, Affan Denk, Elif Tukenmez Tigen, Ceyda Necan, Aliye Bastug, Ahmet Sahin, Cinar Ozturk, Hamdi Sözen, Çiğdem Kader, Mustafa Altindiş, Şafak Kaya, Selçuk Kaya, Mehmet Ulug, Servet Kolgelier, Gül Durmuş, Kamuran Turker, Ahmet Karakaş, Gülden Ersöz, Pinar Korkmaz, Rukiye Pinar Bölüktaş, Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı, Şahin, Ahmet Melih, Karacaer, Zehra, Cakir, Banu, Erdem, Hakan, Ugurlu, Kenan, Durmus, Gul, Ince, Nevin Koc, Ozturk, Cinar, Hasbun, Rodrigo, Batirel, Ayse, Yilmaz, Esmeray Mutlu, Bozkurt, Ilkay, Sunbul, Mustafa, Aynioglu, Aynur, Atilla, Aynur, Erbay, Ayse, Inci, Ayse, Kader, Cigdem, Tigen, Elif Tukenmez, Karaahmetoglu, Gokhan, Coskuner, Seher Ayten, Dik, Ebru, Tarakci, Huseyin, Tosun, Selma, Korkmaz, Fatime, Kolgelier, Servet, Karadag, Fatma Yilmaz, Erol, Serpil, Turker, Kamuran, Necan, Ceyda, Sahin, Ahmet Melih, Ergen, Pinar, Iskender, Gulsen, Korkmaz, Pinar, Eroglu, Esma Gulesen, Durdu, Yasemin, Ulug, Mehmet, Deniz, Suna Secil, Koc, Filiz, Alpat, Saygin Nayman, Oztoprak, Nefise, Evirgen, Omer, Sozen, Hamdi, Dogan, Mustafa, Kaya, Selcuk, Kaya, Safak, Altindis, Mustafa, Aslan, Emel, Tekin, Recep, Sezer, Busra Ergut, Ozdemir, Kevser, Ersoz, Gulden, Sahin, Ahmet, Celik, Ilhami, Aydin, Emsal, Bastug, Aliye, Harman, Rezan, Ozkaya, Hacer Deniz, Parlak, Emine, Yavuz, Ilknur, Sacar, Suzan, Comoglu, Senol, Yenilmez, Ercan, Sirmatel, Fatma, Balkan, Ilker Inanc, Alpay, Yesim, Hatipoglu, Mustafa, Denk, Affan, Senol, Gunes, Bitirgen, Mehmet, Geyik, Mehmet Faruk, Guner, Rahmet, Kadanali, Ayten, Karakas, Ahmet, Namiduru, Mustafa, Udurgucu, Hatice, Boluktas, Rukiye Pinar, Karagoz, Ergenekon, Ormeci, Necati, Karacaer, Z, Cakir, B, Erdem, H, Ugurlu, K, Durmus, G, Ince, NK, Ozturk, C, Hasbun, R, Batirel, A, Yilmaz, EM, Bozkurt, I, Sunbul, M, Aynioglu, A, Atilla, A, Erbay, A, Inci, A, Kader, C, Tigen, ET, Karaahmetoglu, G, Coskuner, SA, Dik, E, Tarakci, H, Tosun, S, Korkmaz, F, Kolgelier, S, Karadag, FY, Erol, S, Turker, K, Necan, C, Sahin, AM, Ergen, P, Iskender, G, Korkmaz, P, Eroglu, EG, Durdu, Y, Ulug, M, Deniz, SS, Koc, F, Alpat, SN, Oztoprak, N, Evirgen, O, Sozen, H, Dogan, M, Kaya, S, Altindis, M, Aslan, E, Tekin, R, Sezer, BE, Ozdemir, K, Ersoz, G, Sahin, A, Celik, I, Aydin, E, Bastug, A, Harman, R, Ozkaya, HD, Parlak, E, Yavuz, I, Sacar, S, Comoglu, S, Yenilmez, E, Sirmatel, F, Balkan, II, Alpay, Y, Hatipoglu, M, Denk, A, Senol, G, Bitirgen, M, Geyik, MF, Guner, R, Kadanali, A, Karakas, A, Namiduru, M, Udurgucu, H, Boluktas, RP, Karagoz, E, Ormeci, N, Sakarya Üniversitesi/Tıp Fakültesi/Temel Tıp Bilimleri Bölümü, Altındiş, Mustafa, Tıp Fakültesi, RTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Öztürk, Çınar, MÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Sözen, Hamdi, Zonguldak Bülent Ecevit Üniversitesi, Halk Sağlığı, BAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Sırmatel, Fatma, and OMÜ

Subjects
antivirus agent, Male, demography, MARITAL-STATUS, Turkey, Cross-sectional study, IMPACT, Disease, DETERMINANTS, Turkey (republic), 0302 clinical medicine, Quality of life, antiviral therapy, Health Status Indicators, Prospective Studies, 030212 general & internal medicine, Prospective cohort study, The Hepatitis B Quality of Life Instrument, food and beverages, clinical trial, General Medicine, Middle Aged, Hepatitis B, humanities, Chronic hepatitis B infection, Female, 030211 gastroenterology & hepatology, HEALTH, prospective study, Adult, medicine.medical_specialty, Chronic Hepatitis B Infection, quality of life assessment, psychology, Antiviral Agents, Article, Interviews as Topic, 03 medical and health sciences, Hepatitis B, Chronic, Chronic hepatitis, UTILITIES, Internal medicine, medicine, cross-sectional study, Humans, chronic hepatitis B, controlled study, human, Aged, Related factors, business.industry, Research, fungi, Public Health, Environmental and Occupational Health, Hepatitis B Quality of Life, interview, medicine.disease, major clinical study, COMORBIDITIES, hepatitis B surface antigen, multicenter study, Cross-Sectional Studies, Health Care Sciences & Services, Short Form 36, Multi center study, Physical therapy, Quality of Life, business, health status indicator
Abstract

WOS: 000386954300001, PubMed: 27809934, Background: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors. Methods: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant. Results: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided. Conclusions: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results